Procedures Using the Medigus MUSE(TM) System Completed at Florida's Renowned St. Vincent's Hospital

OMER, Israel, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that leading Jacksonville, FL gastroenterologist, Dr. Ali Lankarani, has completed five fundoplication procedures to date using the MUSE system, the highest number of these procedures performed by a single physician in the U.S.

The Medigus Ultrasonic Surgical Endostapler, or MUSE system is used to perform an endoscopic (incisionless) procedure for the long-term treatment of GERD (gastroesophageal reflux disease). Dr. Lankarani is one of a growing number of gastroenterologists in the U.S. to offer the MUSE system as an interventional therapeutic option for his patients who suffer from persistent GERD.

"I strive to continually offer new and quality treatment options at my practice. In my experience, I have not seen anything that addresses the treatment gap between drug therapy and invasive laparoscopic surgery quite like MUSE, a technology for a non-invasive procedure which I believe can offer a long-term, perhaps permanent, solution for GERD," said Dr. Lankarani, Board member of the Advanced Therapeutic Endoscopy Center (ATEC) at the Borland-Groover Clinic. "The procedure is effective, generally well-tolerated and may be completed in about an hour, which are important factors when physicians consider adopting new services."

MUSE merges recent advancements in microvisual, ultrasonic and stapling technology into a single platform, which allows for a single physician or surgeon to perform fundoplication (stapling of the upper part of the stomach, or fundus, to the lower esophageal sphincter). MUSE is FDA cleared and CE marked for the treatment of GERD, and has also has obtained the necessary licenses to market the product in Canada and Israel.

"We value our partnership with Dr. Lankarani and are proud to offer a novel modality to help physicians meet the needs of what we believe to be a growing patient population. GERD can have significant impact on the lives of those who suffer from it, and who thus far have had limited options to find relief. With the MUSE system, we believe that physicians are able to offer a long-term solution without the need for invasive surgery, which may enhance patient outcomes," said Chris Rowland, CEO of Medigus.

To hear directly from Dr. Lankarani about the procedures visit: https://www.youtube.com/watch?v=ALtWD8WX-y8.

About GERD

Gastroesophageal reflux disease (GERD) occurs when the lower esophageal sphincter spontaneously opens or does not properly close after use, thereby allowing for stomach contents to rise into the esophagus, causing heartburn, irritation and potentially other discomforts. It affects approximately 24M Americans each year; 14.5M adults experience GERD symptoms at least twice a week, and 2.4M adults experience severe symptoms. While some patients can attain symptom relief through the use of proton pump inhibiters, or PPIs, (acid reducing medications), there is, however, growing concern around the prolonged chronic use of PPIs, including increased risk of bone fracture, infectious complications, and interference with anti-platelet medication and the adsorption of essential vitamins and minerals. A persistent state of untreatable GERD could potentially lead to Barrett's esophagus, a precancerous state which can lead to esophageal cancer. Patients who suffer from daily GERD are more likely to develop esophageal cancer.